Skip to main content
Market Trend6 min read

Radiopharm Deals Are Up 1200% in 2026 — Here's the Data

Radiopharm deal activity surged 1200% in the six months ending November 2026, jumping from zero deals to 12. The Telix-ITM megadeal at $2.35B TDV and Novartis's $900M Boomray bet signal that Big Pharma's radiopharmaceutical arms race is no longer a hypothesis — it's a balance sheet reality.

AV
Ambrosia Ventures
·Based on 1,400+ transactions

Twelve radiopharmaceutical deals closed between May and November 2026 — up from zero in the prior six months, a 1200% surge that marks the most concentrated burst of radiopharm licensing activity since Novartis acquired Endocyte in 2018. The comparison periods are stark: November 2025 through May 2026 produced not a single disclosed radiopharm transaction, while May 2026 through November 2026 delivered a dozen. This isn't gradual pipeline maturation. This is a land grab triggered by clinical validation, manufacturing scarcity, and Big Pharma's existential need for durable oncology franchises beyond checkpoint inhibitors.

The Data — Radiopharm Deal Activity, Period over Period

PeriodValue
2025-11-10 to 2026-05-100
2026-05-10 to 2026-11-1012
Change+1200.0%

The zero-to-twelve trajectory tells you something critical: this wasn't a slow build. The radiopharm deal trends 2026 pattern resembles ADC licensing in 2020–2021, where a handful of clinical readouts unlocked a cascade of transactions within months. When sophisticated buyers move simultaneously, they're pricing in a thesis that has already cleared their internal risk thresholds. For BD teams tracking radiopharm licensing 2026 dynamics, the window between "emerging" and "expensive" has effectively closed.

What's Driving the Trend

Three forces converged to produce this surge. First, clinical data. Multiple actinium-225 and lutetium-177 programs reported progression-free survival data in mid-2026 that exceeded expectations in metastatic castration-resistant prostate cancer and gastroenteropancreatic neuroendocrine tumors. The Pluvicto franchise had already proven the commercial model — what changed was the breadth of targetable antigens. PSMA was the proof of concept; SSTR2, FAP, CXCR4, and HER2-targeted radioligands are now the expansion thesis. Buyers are no longer debating whether radioligand therapy works. They're debating which targets to own.

Second, manufacturing constraint is functioning as a deal accelerant. Ac-225 supply remains severely bottlenecked globally, with fewer than ten facilities capable of GMP-grade production at commercial scale. This scarcity inverts normal deal economics: instead of buyers holding leverage because assets are plentiful, sellers with credible isotope supply chains command premiums. Telix's $1.65B upfront acquisition of ITM — a company whose core asset is vertically integrated lutetium-177 and Ac-225 production — is the clearest signal that supply chain ownership is now a strategic imperative, not a nice-to-have. Novartis learned this lesson building out its own network post-Endocyte; competitors are learning it at a higher cost basis.

Third, Big Pharma's pipeline math demands it. The PD-1/PD-L1 class is genericizing. ADC competition is intensifying, with over 200 programs in clinical development. GLP-1s are reshaping cardiometabolic portfolios but offer limited oncology relevance. Radioligand therapy is one of the few modalities where differentiated clinical outcomes can still justify premium pricing and where competitive density remains relatively low. For a pharma BD team evaluating capital allocation across modalities, radiopharm assets offer something rare: a plausible path to first-in-class or best-in-class positioning in solid tumors without competing against 30 other clinical programs targeting the same biology. Check our Deal Benchmarks for current valuation comparables across modalities.

Notable Deals

LicensorLicenseeUpfrontTDVDate
BoomrayNovartis—$900M2026-09-29
BoomRay PharmaceuticalsNovartis—$900M2026-09-22
Isotope Technologies Munich (ITM)Telix Pharmaceuticals$1650M$2350M2026-09-21
ITM Isotope Technologies MunichTelix$1650M$2350M2026-09-21
Ratio TherapeuticsRayzeBio——2026-09-15

Telix-ITM ($2.35B TDV, $1.65B upfront): This is the defining transaction of the cycle. Telix didn't buy a pipeline — it bought a production platform. ITM's n.c.a. lutetium-177 manufacturing and Ac-225 program represent the kind of vertically integrated supply chain that turns a radiopharm company from a clinical-stage licensor into a platform. The $1.65B upfront — roughly 70% of total deal value — signals Telix's conviction and its unwillingness to let milestone risk dilute the acquisition thesis. For context, this upfront-to-TDV ratio is well above the ~40% median we track at Solidus for oncology licensing deals, indicating a seller's market dynamic.

Novartis-Boomray ($900M TDV): Novartis extending its radiopharm portfolio beyond Pluvicto was expected; the size of the bet was not. The $900M TDV for what appears to be a preclinical-to-early-clinical stage asset reflects Novartis's strategic premium for targets that complement its existing PSMA franchise. Novartis is building a radioligand therapy platform, not just a product line, and Boomray's undisclosed target likely addresses a gap in that architecture. The absence of disclosed upfront terms suggests a milestone-heavy structure — a pattern consistent with earlier-stage radiopharm licensing 2026 deals where buyers are managing binary clinical risk.

RayzeBio-Ratio Therapeutics: Bristol-Myers Squibb's RayzeBio subsidiary acquiring Ratio Therapeutics — with neither upfront nor TDV disclosed — is strategically significant despite the opacity. Ratio's core technology platform focuses on optimized chelator chemistry and novel linker systems for radiopharmaceuticals. This is an infrastructure play: RayzeBio is acquiring the tools to build better radioligands, not just individual drug candidates. Expect this pattern — platform acquisitions over single-asset licenses — to accelerate as the modality matures.

What This Means for BD Teams Right Now

This is unambiguously a seller's market for radiopharm assets, and the data supports aggressive positioning for licensors. Twelve deals in six months with multiple transactions exceeding $900M TDV means buyers are competing for a limited pool of credible assets. If you hold a differentiated radioligand program — particularly one with Ac-225 compatibility, novel target biology, or integrated manufacturing — your leverage is at a cyclical peak.

For buyers, the tactical calculus is more nuanced. Waiting is expensive. Every quarter of delay increases the probability that your preferred target gets locked up by a competitor, and the supply-chain constraints mean that even undifferentiated assets with isotope access are commanding premiums. The smart play is to move fast on platform deals (manufacturing, chelation chemistry, isotope supply) while being disciplined on single-asset licenses where clinical risk remains high. Structure accordingly: higher upfronts buy exclusivity and seller commitment; milestone-heavy structures signal hesitation that sophisticated sellers will exploit.

Deal structures are shifting. The Telix-ITM deal's 70% upfront-to-TDV ratio sets a new benchmark for mature radiopharm assets. Earlier-stage deals are likely to settle in the 25–35% range, but expect sellers to push for opt-in structures, co-development rights, and manufacturing control provisions that were uncommon 18 months ago. Royalty rates are compressing upward: double-digit royalties on net sales are becoming standard for differentiated programs. Use Deal Benchmarks to compare your term sheet against verified recent transactions.

The radiopharm deal window is open, but it won't stay this favorable for sellers indefinitely. Manufacturing capacity is expanding — BWXT, Niowave, and several DOE-adjacent entities are scaling Ac-225 production. When supply constraints ease, the structural premium embedded in current valuations will compress. Sellers: close your deals in the next two to three quarters. Buyers: lock in supply-chain positions now before production capacity becomes commoditized and the premium shifts entirely to clinical differentiation.

Benchmark your deal against current market rates — run your terms through the Ambrosia calculator to see where your radiopharm transaction sits relative to the 12 deals closed this cycle. Whether you're structuring upfronts, milestones, or royalty tiers, Solidus gives you the verified comps your deal team needs.

More from the Blog

Deal Intelligence

Ready to Benchmark Your Deal?

Get instant, data-driven deal terms powered by 1,400+ verified biopharma transactions across 12 therapeutic areas.